Tu sei qui
A86033 - Health Economics, Policy and Management
Anno Accademico 2020/2021
STEFANO CAPRI (Tit.)
- Secondo Ciclo Semestrale
- Modalità d'Erogazione
- Lingua Insegnamento
|[LM77A] Economia Aziendale e Management - Classe LM-77||[PDS0-2019 - Ord. 2019] comune||2||18|
The novel coronavirus pandemic has spawned intertwined health care crises that reveal and compound deep underlying problems in the health care systems. In so doing, however, the pandemic points the way toward reforms that could improve our ability not only to cope with likely future epidemics but also to serve the basic health care needs of our contries. Should we worry about the economy when lives are at stake? We will see in this Course how to estimate the monetary value of the deaths prevented from the Covid-19 confinement measures (e.g. lockdown). and the value of "flattening the curve of infections.
In addition to being one of the most important "goods" consumed in our lives, health care spending accounts on average for approximately 9% of GDP in the OECD countries. How we choose to provide and pay for health care has large direct welfare impacts on the consumers and producers of health care nationwide while also being key ingredients into overall national economic performance.
This course presents an overview of the business of health and how a variety of health care organizations have gained, sustained, and lost competitive advantage amidst intense competition, widespread regulation, high interdependence, and massive technological, economic, social, and political changes -; and the role of innovation in that process. Particular attention will be paid to the pharmaceutical industry.
Specifically, using competitive analysis as our framework, we will evaluate the challenges health care organizations are facing, identify their past responses, and explore how they are using innovation as a strategy to manage these challenges (and emerging ones) more effectively.
Students will develop generalized skills in economic evaluation analysis (cost-effectiveness techniques), assessment of a specific market structure and performance (pharma industry), and understanding of the major issues related to the government decisions in healthcare resource allocation.
We focus on issues that differentiate the healthcare market from most others, including:
• Introduction to Health Economics
• Data on healthcare systems
• Supply side
• Demand side and monopsony
• Patent system
• Merger & Acquisitions (M&A)
• Research & Development: process and costs
• Innovation as a factor in health technology assessment
• Cost-effectiveness analysis
• Pricing and reimbursement of drugs
The course will consist of 16 hours (4 sessions).
Students will be valuated with a written exam or, alternatively, with a group work that students will deliver at the end of the course, depending on the number of students. More details on the exam will be discussed in class.
All course readings and class presentations are required for the exam. The main concepts/takeaways from readings will be discussed in class and are fair game for exam questions. You are not expected to remember details of specific dates, companies, minor statistics etc. Class presentation will be posted after each lecture on the Course website.
1. Pharmaceutical pricing policies. Management sciences for health 2012, Chapter 9, pag. 1-22.
2. Baldi A. Pharmacoeconomics: Principles, Methods and Economic Evaluation of Drug Therapies. PhTechMed, 2013, Vol. 2:362-369.
The exam consists of writing an essay of about 2,700-3,000 words. The subject will be decided during the lessons with the students.